This is my thirteenth Ligand article, following my most recent 06/2026's "Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator" In Aggregator, I ra ...

We have followed Natera closely over the years, highlighting the stock at different price points - December 21, 2022, when it was trading around $41.75, and August 23, 2024, when it was at $122.82.

In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.

Chronic kidney disease is a global epidemic affecting ≈10% of adults worldwide. Women have a higher prevalence of chronic ...

Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.

Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We ...

Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board ...